Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Obsessive-Compulsive Disorder - Overview
Obsessive-Compulsive Disorder - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Obsessive-Compulsive Disorder - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Amorsa Therapeutics Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Canbis Science Inc
Omeros Corp
Phytecs
Rugen Therapeutics R&D (Shanghai) Co Ltd
Seropeutics LLC
Obsessive-Compulsive Disorder - Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Obsessive-Compulsive Disorder - Dormant Projects
Obsessive-Compulsive Disorder - Discontinued Products
Obsessive-Compulsive Disorder - Product Development Milestones
Featured News & Press Releases
Sep 16, 2019: Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor in development for addiction
Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Obsessive-Compulsive Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Obsessive-Compulsive Disorder, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Addex Therapeutics Ltd, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Biogen Inc, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Cannabis Science Inc, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Phytecs, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, H1 2020
Obsessive-Compulsive Disorder - Pipeline by Seropeutics LLC, H1 2020
Obsessive-Compulsive Disorder - Dormant Projects, H1 2020
Obsessive-Compulsive Disorder - Discontinued Products, H1 2020